We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) said Wednesday that it will build a joint lab with partner Transgene SA (TNG.FR) to manufacture viral vectors such as MUC1, a drug developed by Transgene that targets cancer immunotherapy.
The lab will be located in Lyon and will cost EUR10 million over two years, with each company financing half the cost, Sanofi and Transgene said in a joint statement.
The two companies had announced a partnership in March last year.
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions